Skip to main content

The Globe and Mail

Health Minister accepts 'prudent' advice not to fund MS treatment

Leona Aglukkaq has accepted the recommendation of the federal agency that funds health research, which said this week it is too soon to conduct clinical trials of a controversial new procedure to treat multiple sclerosis.

"I feel the most prudent course of action at this time is to accept the recommendation of the country's leading researchers," the federal Health Minister told a news conference on Wednesday.

Ms. Aglukkaq said the procedure, which is called liberation therapy, is invasive and is too risky to put to human trials.

Story continues below advertisement

The Canadian Institutes of Health Research convened a panel of experts that decided unanimously there is no evidence that the procedure is safe, that it works or that the science behind it is sound.

The CIHR recommended that clinical trials wait for the results of seven studies that have been funded by the Multiple Sclerosis Society of Canada to determine if the disease is related to the flow of blood to the brain.

Liberation therapy has been hotly contested among MS patients since Italian doctor Paolo Zamboni published results of a recent study that posits the condition as a vascular disorder caused by vein blockages that lead to a build-up of iron rather than an auto-immune disease. Dr. Zamboni says he has treated MS with a simple surgical procedure - angioplasty.

Saskatchewan jumped ahead of the rest of the country in saying it would fund clinical trials of the procedure, which has raised the hopes of the many Canadians afflicted with the debilitating illness.

News the government of Canada is not prepared to move quickly to fund clinical trials will be a major disappointment to many MS patients, who are pinning their hopes on the procedure to treat what is still an incurable disease. Some patients are paying thousands of dollars of their own money to have the procedure performed in other countries.

Yves Savoie, the president of the MS Society said his organization will monitor the results of the studies it is funding and if they suggest the procedure works, they will recommend that the trial phase be quickly implemented.

Ms. Aglukkaq said she welcomed the resources that provinces like Saskatchewan have directed towards the issue.

Story continues below advertisement

But Mr. Savoie said any real clinical trial would require a pan-Canadian approach involving at least 1,000 patients. "A single province, or a single site, would simply not be a way to get to the definitive answers that we all want."

Saskatchewan has said it will proceed with trials regardless of the direction taken by the federal government.

Report an error Licensing Options
About the Author
Parliamentary reporter

Gloria Galloway has been a journalist for almost 30 years. She worked at the Windsor Star, the Hamilton Spectator, the National Post, the Canadian Press and a number of small newspapers before being hired by The Globe and Mail as deputy national editor in 2001. Gloria returned to reporting two years later and joined the Ottawa bureau in 2004. More

Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Combined Shape Created with Sketch.

Globe Newsletters

Get a summary of news of the day

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.